BAVA Phase II smallpox data

Bavarian Nordic (CSE:BAVA) said in a Phase II study in 165 healthy volunteers, its Imvamune MVA smallpox vaccine was safe and well tolerated at the three doses tested. No serious adverse reactions wer...